Allurion Technologies Inc.

Company Overview

Business Model: Allurion Technologies, Inc. ("Allurion" or "the Company") is a vertically integrated medical device company focused on metabolically healthy weight loss. Its core offering, the Allurion Program, features the Allurion Smart Capsule, the world’s first and only swallowable, Procedureless™ intragastric balloon for weight loss, which does not require surgery, endoscopy, or anesthesia for placement. The program also includes the Allurion Virtual Care Suite ("VCS"), an artificial intelligence ("AI")-powered digital therapeutic providing remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth. Revenue is primarily generated from the sale of the Allurion Smart Capsule to distributors and healthcare providers.

Market Position: Allurion is pioneering metabolically healthy weight loss, targeting an estimated two billion people globally who are overweight. The global obesity treatment market is projected to reach $54 billion by 2030. The Company has treated over 200,000 patients commercially with the Allurion Smart Capsule in over 50 countries outside of the United States. Allurion estimates a $10 billion total addressable market for the Allurion Smart Capsule in the United States, representing approximately 10 million adults. The Allurion Program is positioned as a synergistic therapy with glucagon-like peptide 1 ("GLP-1") receptor agonists, particularly for GLP-1 discontinuers, and aims to deliver longer-lasting results by reducing fat while preserving or increasing muscle mass.

Recent Strategic Developments:

• FDA Approval: On February 20, 2026, the U.S. Food and Drug Administration ("FDA") granted PMA approval for the Allurion Gastric Balloon System (AGBS), featuring the Allurion Smart Capsule, for short-term limited weight loss in adults with BMI ≥ 30 kg/m2 and ≤ 40 kg/m2.
• Warrant Inducement: On February 24, 2026, the Company entered into an inducement offer letter to amend existing warrants, lowering the exercise price to $1.15 per share. This resulted in the exercise of 2,659,565 shares of Common Stock for approximately $3.1 million in gross proceeds and the issuance of new warrants to purchase up to 5,319,130 shares.
• Exchange Agreement with RTW: On November 11, 2025, Allurion entered into an agreement with entities managed by RTW to exchange all principal and accrued interest of convertible senior secured notes, and obligations under revenue interest financing agreements, for shares of a newly issued class of Series B convertible preferred stock. Stockholder approval for this issuance was obtained on December 18, 2025.
• Product Innovation: In 2024, Allurion released a next-generation Allurion Smart Capsule with a smaller capsule, more radiopaque catheter, and enhanced fill valve to increase ease of use and efficiency.
• VCS Expansion: In April 2024, the VCS was launched in the United States for patients utilizing other weight loss treatments, including anti-obesity medications and bariatric surgery.
• Workforce Restructuring: In August 2025, the Company reduced its workforce by approximately 70 roles (65%) to reduce operating expenses and align with business needs, with the majority completed in Q3 and Q4 2025.

Geographic Footprint: Allurion's products are sold in over 50 countries globally. The Company operates subsidiaries in the United States, France, the United Arab Emirates, the United Kingdom, Italy, Spain, Australia, and Mexico.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 62.8%
• Operating Margin: -197.9%
• Net Margin: -188.8%

Investment in Growth (2025):

• R&D Expenditure: $7.57 million (49.7% of revenue)
• Capital Expenditures: $0 million
• Strategic Investments: The Company is exploring combination approaches with GLP-1 receptor agonists in future clinical trials.

Business Segment Analysis

Allurion operates its business in a single operating segment and as one reporting unit.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed for 2025 or 2024.
• Dividend Payments: Allurion does not intend to pay cash dividends for the foreseeable future, with any future determination at the discretion of the Board of Directors.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $5.41 million
• Total Debt: $75.77 million (Current portion of convertible notes payable: $28.07 million; Revenue Interest Financing liability: $47.70 million)
• Net Cash Position: $(70.36) million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: RTW Convertible Notes mature on April 16, 2031. The Revenue Interest Financing Agreement matures on December 31, 2030.

Cash Flow Generation (2025):

• Operating Cash Flow: $(28.95) million
• Free Cash Flow: $(28.95) million (Operating Cash Flow - Capital Expenditures)
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Allurion Smart Capsules are manufactured and assembled in-house at the Company's 10,000 square foot, ISO 13485 certified manufacturing facility in Natick, Massachusetts. The operational philosophy emphasizes compliance with FDA's Quality System Regulation ("QSR") and the European Union’s Quality Management Systems requirements (ISO 13485:2016). The Allurion Virtual Care Suite ("VCS") provides digital service delivery, integrating AI-powered remote patient monitoring and a behavior change program.

Supply Chain Architecture: Key Suppliers & Partners:

• Components & Sub-assemblies: Relies on suppliers for extruded film, stylets, filler kits, accessories, and scales. Some critical components are sourced from single suppliers, with whom the Company typically maintains at least a six-month supply.
• Manufacturing: In-house production team in Natick, Massachusetts.
• Sterilization: Relies on third-party providers for sterilization.

Facility Network:

• Corporate Headquarters: Natick, Massachusetts (approx. 9,900 sq ft, lease expires February 28, 2028).
• Manufacturing: Natick, Massachusetts (approx. 10,200 sq ft, lease expires February 28, 2028).
• Research & Development: R&D labs are part of the Natick facilities.
• Distribution: Previously leased warehouse space in Hudson, Massachusetts (9,800 sq ft) which expired on February 28, 2026.

Operational Metrics:

• Quality Indicators: Commercial experience with over 200,000 Allurion Smart Capsule units has shown a serious adverse event ("SAE") rate of less than 0.2%, similar to reported literature.

Market Access & Customer Relationships

Go-to-Market Strategy: Allurion employs a multi-faceted business-to-business-to-consumer ("B2B2C") marketing strategy. Distribution Channels:

• Direct Sales: Operates a direct sales force in approximately 20 countries.
• Channel Partners: Utilizes distributors in certain countries, providing clinical training and support.
• Digital Platforms: The Allurion Virtual Care Suite (VCS) mobile app and clinic dashboard serve as digital platforms for patient support and provider monitoring.

Customer Portfolio: Enterprise Customers: Targets bariatric surgeons, gastroenterologists, plastic surgeons, and other healthcare providers. The Allurion Smart Capsule's procedureless nature allows a wider group of healthcare providers to offer the program.

• Customer Concentration: For 2025, no single customer represented 10% or more of total revenue. For 2024, one customer represented 14% of accounts receivable.

Geographic Revenue Distribution (2025):

• Spain: $2.15 million
• Italy: $1.84 million
• All other countries: $11.24 million (includes five countries each contributing 4%-9% of total revenue, and 44 other countries).
• Growth Markets: Strategy includes deepening global presence in existing markets and launching in new markets, including the United States following FDA approval.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The weight loss and obesity management industries are highly competitive, rapidly changing, and influenced by new product introductions, clinical research, corporate combinations, and regulatory actions. The global obesity treatment market is expected to reach $54 billion by 2030, driven by rising obesity rates (projected one billion obese globally by 2030). GLP-1 receptor agonists have become popular, but face challenges with adherence (30% discontinue in first month, 65% in first year) and muscle mass loss (approx. 40% of total weight lost).

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Intragastric Balloons (outside US): SC MedSil, Medicone, Spatz Laboratories.
• Intragastric Balloons (US): Boston Scientific Corporation (acquired Apollo Endosurgery), ReShape Lifesciences, Inc. (now Medtimo, not currently commercializing), Spatz FGIA Inc. (All require endoscopy and anesthesia for placement and/or removal).
• Pharmaceuticals: Novo Nordisk A/S, Eli Lilly & Co., Roche Holding AG, GlaxoSmithKline plc, Arena Pharmaceuticals, Inc., VIVUS, Inc., Orexigen Therapeutics, Inc.

Emerging Competitive Threats: Compounded GLP-1 drugs and other new or alternative products that are safer, more effective, or easier to use.

Competitive Response Strategy: Allurion aims to overcome limitations of other treatments through its Procedureless™ technology, favorable safety profile, AI-powered end-to-end weight management platform, life-changing clinical outcomes, attractive economics for patients and providers, broad patent portfolio, and proprietary manufacturing capabilities. The Company is also exploring combination approaches with low-dose GLP-1s in future clinical trials to address GLP-1 shortcomings.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Highly competitive and rapidly changing weight loss and obesity management industries. Risk of new product introductions, clinical research, and regulatory changes impacting demand.
• Technology Disruption: Competitors developing safer, more effective, or easier-to-use products (medical devices or drugs like GLP-1s) could reduce or eliminate commercial opportunities.
• Customer Concentration: Dependence on healthcare providers and third-party distributors, with limited direct control over their sales efforts. Failure to collect receivables from them could adversely affect financial position.
• Market Acceptance: Failure of the Allurion Smart Capsule to achieve and maintain market acceptance, especially in the United States where commercial history is limited, could result in sales below expectations.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Dependence on a limited number of single-source suppliers for critical components, sub-assemblies, and materials, making the Company vulnerable to supply shortages and price fluctuations.
• Geographic Concentration: International operations expose the Company to business, regulatory, political, operational, financial, and economic risks in over 50 countries, including emerging markets.
• Capacity Constraints: Need to increase manufacturing capabilities over time to satisfy increased demand, with no experience manufacturing in such quantities.
• Workforce Management: Changes in business and operations, including a significant reduction in force (65% in 2025), place demands on management and infrastructure, potentially leading to delays, decreased satisfaction, or employee attrition.
• Product Liability: Inherent risk of product liability exposure related to the sale or misuse of the Allurion Smart Capsule, potentially leading to costly litigation, reputational harm, or regulatory actions.

Financial & Regulatory Risks

• Going Concern: Recurring operating losses and cash outflows, expectation of continued losses, and noncompliance with financial covenants raise substantial doubt about the Company's ability to continue as a going concern.
• Debt Burden: Significant amount of debt ($75.77 million as of December 31, 2025), with financial covenants (minimum liquidity, minimum revenue) that the Company has been out of compliance with, potentially leading to debt acceleration.
• Funding Availability: Need for additional funds to support operations, which may not be available on acceptable terms or at all, forcing delays or suspension of development and commercialization efforts.
• Regulatory Approval & Compliance: Ongoing regulatory obligations and review post-approval (e.g., FDA PMA approval in US), potential for withdrawal or modification of approvals if adverse events occur, and penalties for non-compliance.
• Reimbursement: Limited third-party reimbursement for products, requiring reliance on self-pay practice management and patients' willingness to pay out-of-pocket.
• Financial Statement Restatement: Previously restated financial statements for multiple periods, leading to unanticipated costs, legal proceedings, regulatory actions, and potential adverse effects on investor confidence and share price.

Geopolitical & External Risks

• Geopolitical Exposure: Unstable global economic and geopolitical conditions (e.g., military conflicts, trade wars) could adversely affect business, financial condition, and results of operations.
• Trade Relations: Changes in U.S. federal policy, including tariffs, could impact global economic conditions and financial markets.
• Climate-related Issues: Evolving government regulations (e.g., SEC Climate Disclosure Rules) may impose additional costs or expose the Company to reputational risks.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Allurion Smart Capsule Enhancements: Focus on improving efficacy and ease of use, including a smaller capsule, more radiopaque catheter, and enhanced fill valve (released in 2024).
• Drug Delivery Platform: Intends to implement new features to potentially enable the Allurion Smart Capsule as a platform technology for drug delivery.
• AI Platform (Allurion Iris): Leverages machine learning for remote patient monitoring, key insights, and workflow streamlining (e.g., Success Predictor, Coach Iris). Innovation Pipeline:
• GLP-1 Combination Trials: Clinical pipeline focused on gathering additional evidence on the safety and efficacy of combining the Allurion Program with low-dose GLP-1 medications, with initial case series showing favorable results (e.g., 20.3% weight loss with semaglutide, 23% with tirzepatide, with muscle mass preservation/increase).

Intellectual Property Portfolio:

• Patent Strategy: Owns or has rights to a broad portfolio of intellectual property.
• Patent Holdings: As of December 31, 2025, 23 issued and 4 pending patents in the U.S. related to the Allurion Smart Capsule (swallowable, self-deflating, naturally passing gastric balloon, fill/release valves, deployment methods). Additionally, 43 issued and 4 pending patents outside the U.S. (generally paralleling the U.S. portfolio in 17 countries, including 3 Unitary European patents).
• Expiration Dates: Issued patents are expected to expire between February 21, 2033, and November 27, 2040.
• Trademarks: 65 registered trademarks in 40 jurisdictions (medical devices, downloadable software, digital scale, medical services).
• IP Litigation: The medical device industry is characterized by patent litigation, and the Company could become subject to adversarial proceedings.

Technology Partnerships: Not explicitly detailed, but the Company engages consultants and third-party information technology and security providers for its cybersecurity risk management program and AI platform development.

Leadership & Governance

Executive Leadership Team (as of March 17, 2026)

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 62.8%
• Operating Margin: -197.9%
• Net Margin: -188.8%

Investment in Growth (2025):

• R&D Expenditure: $7.57 million (49.7% of revenue)
• Capital Expenditures: $0 million
• Strategic Investments: The Company is exploring combination approaches with GLP-1 receptor agonists in future clinical trials.

Business Segment Analysis

Allurion operates its business in a single operating segment and as one reporting unit.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed for 2025 or 2024.
• Dividend Payments: Allurion does not intend to pay cash dividends for the foreseeable future, with any future determination at the discretion of the Board of Directors.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $5.41 million
• Total Debt: $75.77 million (Current portion of convertible notes payable: $28.07 million; Revenue Interest Financing liability: $47.70 million)
• Net Cash Position: $(70.36) million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: RTW Convertible Notes mature on April 16, 2031. The Revenue Interest Financing Agreement matures on December 31, 2030.

Cash Flow Generation (2025):

• Operating Cash Flow: $(28.95) million
• Free Cash Flow: $(28.95) million (Operating Cash Flow - Capital Expenditures)
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Allurion Smart Capsules are manufactured and assembled in-house at the Company's 10,000 square foot, ISO 13485 certified manufacturing facility in Natick, Massachusetts. The operational philosophy emphasizes compliance with FDA's Quality System Regulation ("QSR") and the European Union’s Quality Management Systems requirements (ISO 13485:2016). The Allurion Virtual Care Suite ("VCS") provides digital service delivery, integrating AI-powered remote patient monitoring and a behavior change program.

Supply Chain Architecture: Key Suppliers & Partners:

• Components & Sub-assemblies: Relies on suppliers for extruded film, stylets, filler kits, accessories, and scales. Some critical components are sourced from single suppliers, with whom the Company typically maintains at least a six-month supply.
• Manufacturing: In-house production team in Natick, Massachusetts.
• Sterilization: Relies on third-party providers for sterilization.

Facility Network:

• Corporate Headquarters: Natick, Massachusetts (approx. 9,900 sq ft, lease expires February 28, 2028).
• Manufacturing: Natick, Massachusetts (approx. 10,200 sq ft, lease expires February 28, 2028).
• Research & Development: R&D labs are part of the Natick facilities.
• Distribution: Previously leased warehouse space in Hudson, Massachusetts (9,800 sq ft) which expired on February 28, 2026.

Operational Metrics:

• Quality Indicators: Commercial experience with over 200,000 Allurion Smart Capsule units has shown a serious adverse event ("SAE") rate of less than 0.2%, similar to reported literature.

Market Access & Customer Relationships

Go-to-Market Strategy: Allurion employs a multi-faceted business-to-business-to-consumer ("B2B2C") marketing strategy. Distribution Channels:

• Direct Sales: Operates a direct sales force in approximately 20 countries.
• Channel Partners: Utilizes distributors in certain countries, providing clinical training and support.
• Digital Platforms: The Allurion Virtual Care Suite (VCS) mobile app and clinic dashboard serve as digital platforms for patient support and provider monitoring.

Customer Portfolio: Enterprise Customers: Targets bariatric surgeons, gastroenterologists, plastic surgeons, and other healthcare providers. The Allurion Smart Capsule's procedureless nature allows a wider group of healthcare providers to offer the program.

• Customer Concentration: For 2025, no single customer represented 10% or more of total revenue. For 2024, one customer represented 14% of accounts receivable.

Geographic Revenue Distribution (2025):

• Spain: $2.15 million
• Italy: $1.84 million
• All other countries: $11.24 million (includes five countries each contributing 4%-9% of total revenue, and 44 other countries).
• Growth Markets: Strategy includes deepening global presence in existing markets and launching in new markets, including the United States following FDA approval.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The weight loss and obesity management industries are highly competitive, rapidly changing, and influenced by new product introductions, clinical research, corporate combinations, and regulatory actions. The global obesity treatment market is expected to reach $54 billion by 2030, driven by rising obesity rates (projected one billion obese globally by 2030). GLP-1 receptor agonists have become popular, but face challenges with adherence (30% discontinue in first month, 65% in first year) and muscle mass loss (approx. 40% of total weight lost).

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Intragastric Balloons (outside US): SC MedSil, Medicone, Spatz Laboratories.
• Intragastric Balloons (US): Boston Scientific Corporation (acquired Apollo Endosurgery), ReShape Lifesciences, Inc. (now Medtimo, not currently commercializing), Spatz FGIA Inc. (All require endoscopy and anesthesia for placement and/or removal).
• Pharmaceuticals: Novo Nordisk A/S, Eli Lilly & Co., Roche Holding AG, GlaxoSmithKline plc, Arena Pharmaceuticals, Inc., VIVUS, Inc., Orexigen Therapeutics, Inc.

Emerging Competitive Threats: Compounded GLP-1 drugs and other new or alternative products that are safer, more effective, or easier to use.

Competitive Response Strategy: Allurion aims to overcome limitations of other treatments through its Procedureless™ technology, favorable safety profile, AI-powered end-to-end weight management platform, life-changing clinical outcomes, attractive economics for patients and providers, broad patent portfolio, and proprietary manufacturing capabilities. The Company is also exploring combination approaches with low-dose GLP-1s in future clinical trials to address GLP-1 shortcomings.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Highly competitive and rapidly changing weight loss and obesity management industries. Risk of new product introductions, clinical research, and regulatory changes impacting demand.
• Technology Disruption: Competitors developing safer, more effective, or easier-to-use products (medical devices or drugs like GLP-1s) could reduce or eliminate commercial opportunities.
• Customer Concentration: Dependence on healthcare providers and third-party distributors, with limited direct control over their sales efforts. Failure to collect receivables from them could adversely affect financial position.
• Market Acceptance: Failure of the Allurion Smart Capsule to achieve and maintain market acceptance, especially in the United States where commercial history is limited, could result in sales below expectations.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Dependence on a limited number of single-source suppliers for critical components, sub-assemblies, and materials, making the Company vulnerable to supply shortages and price fluctuations.
• Geographic Concentration: International operations expose the Company to business, regulatory, political, operational, financial, and economic risks in over 50 countries, including emerging markets.
• Capacity Constraints: Need to increase manufacturing capabilities over time to satisfy increased demand, with no experience manufacturing in such quantities.
• Workforce Management: Changes in business and operations, including a significant reduction in force (65% in 2025), place demands on management and infrastructure, potentially leading to delays, decreased satisfaction, or employee attrition.
• Product Liability: Inherent risk of product liability exposure related to the sale or misuse of the Allurion Smart Capsule, potentially leading to costly litigation, reputational harm, or regulatory actions.

Financial & Regulatory Risks

• Going Concern: Recurring operating losses and cash outflows, expectation of continued losses, and noncompliance with financial covenants raise substantial doubt about the Company's ability to continue as a going concern.
• Debt Burden: Significant amount of debt ($75.77 million as of December 31, 2025), with financial covenants (minimum liquidity, minimum revenue) that the Company has been out of compliance with, potentially leading to debt acceleration.
• Funding Availability: Need for additional funds to support operations, which may not be available on acceptable terms or at all, forcing delays or suspension of development and commercialization efforts.
• Regulatory Approval & Compliance: Ongoing regulatory obligations and review post-approval (e.g., FDA PMA approval in US), potential for withdrawal or modification of approvals if adverse events occur, and penalties for non-compliance.
• Reimbursement: Limited third-party reimbursement for products, requiring reliance on self-pay practice management and patients' willingness to pay out-of-pocket.
• Financial Statement Restatement: Previously restated financial statements for multiple periods, leading to unanticipated costs, legal proceedings, regulatory actions, and potential adverse effects on investor confidence and share price.

Geopolitical & External Risks

• Geopolitical Exposure: Unstable global economic and geopolitical conditions (e.g., military conflicts, trade wars) could adversely affect business, financial condition, and results of operations.
• Trade Relations: Changes in U.S. federal policy, including tariffs, could impact global economic conditions and financial markets.
• Climate-related Issues: Evolving government regulations (e.g., SEC Climate Disclosure Rules) may impose additional costs or expose the Company to reputational risks.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Allurion Smart Capsule Enhancements: Focus on improving efficacy and ease of use, including a smaller capsule, more radiopaque catheter, and enhanced fill valve (released in 2024).
• Drug Delivery Platform: Intends to implement new features to potentially enable the Allurion Smart Capsule as a platform technology for drug delivery.
• AI Platform (Allurion Iris): Leverages machine learning for remote patient monitoring, key insights, and workflow streamlining (e.g., Success Predictor, Coach Iris). Innovation Pipeline:
• GLP-1 Combination Trials: Clinical pipeline focused on gathering additional evidence on the safety and efficacy of combining the Allurion Program with low-dose GLP-1 medications, with initial case series showing favorable results (e.g., 20.3% weight loss with semaglutide, 23% with tirzepatide, with muscle mass preservation/increase).

Intellectual Property Portfolio:

• Patent Strategy: Owns or has rights to a broad portfolio of intellectual property.
• Patent Holdings: As of December 31, 2025, 23 issued and 4 pending patents in the U.S. related to the Allurion Smart Capsule (swallowable, self-deflating, naturally passing gastric balloon, fill/release valves, deployment methods). Additionally, 43 issued and 4 pending patents outside the U.S. (generally paralleling the U.S. portfolio in 17 countries, including 3 Unitary European patents).
• Expiration Dates: Issued patents are expected to expire between February 21, 2033, and November 27, 2040.
• Trademarks: 65 registered trademarks in 40 jurisdictions (medical devices, downloadable software, digital scale, medical services).
• IP Litigation: The medical device industry is characterized by patent litigation, and the Company could become subject to adversarial proceedings.

Technology Partnerships: Not explicitly detailed, but the Company engages consultants and third-party information technology and security providers for its cybersecurity risk management program and AI platform development.

Leadership & Governance

Executive Leadership Team (as of March 17, 2026)

Allurion has treated over 200,000 patients commercially in over 50 countries outside the United States. The global obesity treatment market is projected to reach $54 billion by 2030, with an estimated two billion people globally overweight. The Company estimates a $10 billion total addressable market for the Allurion Smart Capsule in the United States.

Recent strategic developments include the FDA's PMA approval for the Allurion Gastric Balloon System (AGBS) on February 20, 2026, indicating its use for short-term limited weight loss in adults with BMI ≥ 30 kg/m2 and ≤ 40 kg/m2. The Company also completed a warrant exercise inducement offer in February 2026, generating approximately $3.1 million in gross proceeds. In November 2025, Allurion entered into an Exchange Agreement with RTW to convert existing debt and revenue interest obligations into Series B convertible preferred stock, subject to closing conditions. Product innovation in 2024 included a next-generation Allurion Smart Capsule with improved features, and the VCS was launched in the United States in April 2024 for patients using other weight loss treatments. In August 2025, the Company underwent a significant workforce restructuring, reducing its headcount by approximately 65% (70 roles) to optimize operating expenses.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 62.8%
• Operating Margin: -197.9%
• Net Margin: -188.8%

Investment in Growth (2025):

• R&D Expenditure: $7.57 million (49.7% of revenue)
• Capital Expenditures: $0 million
• Strategic Investments: The Company is exploring combination approaches with GLP-1 receptor agonists in future clinical trials.

Business Segment Analysis

Allurion operates its business in a single operating segment and as one reporting unit.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed for 2025 or 2024.
• Dividend Payments: Allurion does not intend to pay cash dividends for the foreseeable future, with any future determination at the discretion of the Board of Directors.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $5.41 million
• Total Debt: $75.77 million (Current portion of convertible notes payable: $28.07 million; Revenue Interest Financing liability: $47.70 million)
• Net Cash Position: $(70.36) million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: RTW Convertible Notes mature on April 16, 2031. The Revenue Interest Financing Agreement matures on December 31, 2030.

Cash Flow Generation (2025):

• Operating Cash Flow: $(28.95) million
• Free Cash Flow: $(28.95) million (Operating Cash Flow - Capital Expenditures)
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Allurion Smart Capsules are manufactured and assembled in-house at the Company's 10,000 square foot, ISO 13485 certified manufacturing facility in Natick, Massachusetts. The operational philosophy emphasizes compliance with FDA's Quality System Regulation ("QSR") and the European Union’s Quality Management Systems requirements (ISO 13485:2016). The Allurion Virtual Care Suite ("VCS") provides digital service delivery, integrating AI-powered remote patient monitoring and a behavior change program.

Supply Chain Architecture: Key Suppliers & Partners:

• Components & Sub-assemblies: Relies on suppliers for extruded film, stylets, filler kits, accessories, and scales. Some critical components are sourced from single suppliers, with whom the Company typically maintains at least a six-month supply.
• Manufacturing: In-house production team in Natick, Massachusetts.
• Sterilization: Relies on third-party providers for sterilization.

Facility Network:

• Corporate Headquarters: Natick, Massachusetts (approx. 9,900 sq ft, lease expires February 28, 2028).
• Manufacturing: Natick, Massachusetts (approx. 10,200 sq ft, lease expires February 28, 2028).
• Research & Development: R&D labs are part of the Natick facilities.
• Distribution: Previously leased warehouse space in Hudson, Massachusetts (9,800 sq ft) which expired on February 28, 2026.

Operational Metrics:

• Quality Indicators: Commercial experience with over 200,000 Allurion Smart Capsule units has shown a serious adverse event ("SAE") rate of less than 0.2%, similar to reported literature.

Market Access & Customer Relationships

Go-to-Market Strategy: Allurion employs a multi-faceted business-to-business-to-consumer ("B2B2C") marketing strategy. Distribution Channels:

• Direct Sales: Operates a direct sales force in approximately 20 countries.
• Channel Partners: Utilizes distributors in certain countries, providing clinical training and support.
• Digital Platforms: The Allurion Virtual Care Suite (VCS) mobile app and clinic dashboard serve as digital platforms for patient support and provider monitoring.

Customer Portfolio: Enterprise Customers: Targets bariatric surgeons, gastroenterologists, plastic surgeons, and other healthcare providers. The Allurion Smart Capsule's procedureless nature allows a wider group of healthcare providers to offer the program.

• Customer Concentration: For 2025, no single customer represented 10% or more of total revenue. For 2024, one customer represented 14% of accounts receivable.

Geographic Revenue Distribution (2025):

• Spain: $2.15 million
• Italy: $1.84 million
• All other countries: $11.24 million (includes five countries each contributing 4%-9% of total revenue, and 44 other countries).
• Growth Markets: Strategy includes deepening global presence in existing markets and launching in new markets, including the United States following FDA approval.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The weight loss and obesity management industries are highly competitive, rapidly changing, and influenced by new product introductions, clinical research, corporate combinations, and regulatory actions. The global obesity treatment market is expected to reach $54 billion by 2030, driven by rising obesity rates (projected one billion obese globally by 2030). GLP-1 receptor agonists have become popular, but face challenges with adherence (30% discontinue in first month, 65% in first year) and muscle mass loss (approx. 40% of total weight lost).

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Intragastric Balloons (outside US): SC MedSil, Medicone, Spatz Laboratories.
• Intragastric Balloons (US): Boston Scientific Corporation (acquired Apollo Endosurgery), ReShape Lifesciences, Inc. (now Medtimo, not currently commercializing), Spatz FGIA Inc. (All require endoscopy and anesthesia for placement and/or removal).
• Pharmaceuticals: Novo Nordisk A/S, Eli Lilly & Co., Roche Holding AG, GlaxoSmithKline plc, Arena Pharmaceuticals, Inc., VIVUS, Inc., Orexigen Therapeutics, Inc.

Emerging Competitive Threats: Compounded GLP-1 drugs and other new or alternative products that are safer, more effective, or easier to use.

Competitive Response Strategy: Allurion aims to overcome limitations of other treatments through its Procedureless™ technology, favorable safety profile, AI-powered end-to-end weight management platform, life-changing clinical outcomes, attractive economics for patients and providers, broad patent portfolio, and proprietary manufacturing capabilities. The Company is also exploring combination approaches with low-dose GLP-1s in future clinical trials to address GLP-1 shortcomings.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Highly competitive and rapidly changing weight loss and obesity management industries. Risk of new product introductions, clinical research, and regulatory changes impacting demand.
• Technology Disruption: Competitors developing safer, more effective, or easier-to-use products (medical devices or drugs like GLP-1s) could reduce or eliminate commercial opportunities.
• Customer Concentration: Dependence on healthcare providers and third-party distributors, with limited direct control over their sales efforts. Failure to collect receivables from them could adversely affect financial position.
• Market Acceptance: Failure of the Allurion Smart Capsule to achieve and maintain market acceptance, especially in the United States where commercial history is limited, could result in sales below expectations.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Dependence on a limited number of single-source suppliers for critical components, sub-assemblies, and materials, making the Company vulnerable to supply shortages and price fluctuations.
• Geographic Concentration: International operations expose the Company to business, regulatory, political, operational, financial, and economic risks in over 50 countries, including emerging markets.
• Capacity Constraints: Need to increase manufacturing capabilities over time to satisfy increased demand, with no experience manufacturing in such quantities.
• Workforce Management: Changes in business and operations, including a significant reduction in force (65% in 2025), place demands on management and infrastructure, potentially leading to delays, decreased satisfaction, or employee attrition.
• Product Liability: Inherent risk of product liability exposure related to the sale or misuse of the Allurion Smart Capsule, potentially leading to costly litigation, reputational harm, or regulatory actions.

Financial & Regulatory Risks

• Going Concern: Recurring operating losses and cash outflows, expectation of continued losses, and noncompliance with financial covenants raise substantial doubt about the Company's ability to continue as a going concern.
• Debt Burden: Significant amount of debt ($75.77 million as of December 31, 2025), with financial covenants (minimum liquidity, minimum revenue) that the Company has been out of compliance with, potentially leading to debt acceleration.
• Funding Availability: Need for additional funds to support operations, which may not be available on acceptable terms or at all, forcing delays or suspension of development and commercialization efforts.
• Regulatory Approval & Compliance: Ongoing regulatory obligations and review post-approval (e.g., FDA PMA approval in US), potential for withdrawal or modification of approvals if adverse events occur, and penalties for non-compliance.
• Reimbursement: Limited third-party reimbursement for products, requiring reliance on self-pay practice management and patients' willingness to pay out-of-pocket.
• Financial Statement Restatement: Previously restated financial statements for multiple periods, leading to unanticipated costs, legal proceedings, regulatory actions, and potential adverse effects on investor confidence and share price.

Geopolitical & External Risks

• Geopolitical Exposure: Unstable global economic and geopolitical conditions (e.g., military conflicts, trade wars) could adversely affect business, financial condition, and results of operations.
• Trade Relations: Changes in U.S. federal policy, including tariffs, could impact global economic conditions and financial markets.
• Climate-related Issues: Evolving government regulations (e.g., SEC Climate Disclosure Rules) may impose additional costs or expose the Company to reputational risks.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Allurion Smart Capsule Enhancements: Focus on improving efficacy and ease of use, including a smaller capsule, more radiopaque catheter, and enhanced fill valve (released in 2024).
• Drug Delivery Platform: Intends to implement new features to potentially enable the Allurion Smart Capsule as a platform technology for drug delivery.
• AI Platform (Allurion Iris): Leverages machine learning for remote patient monitoring, key insights, and workflow streamlining (e.g., Success Predictor, Coach Iris). Innovation Pipeline:
• GLP-1 Combination Trials: Clinical pipeline focused on gathering additional evidence on the safety and efficacy of combining the Allurion Program with low-dose GLP-1 medications, with initial case series showing favorable results (e.g., 20.3% weight loss with semaglutide, 23% with tirzepatide, with muscle mass preservation/increase).

Intellectual Property Portfolio:

• Patent Strategy: Owns or has rights to a broad portfolio of intellectual property.
• Patent Holdings: As of December 31, 2025, 23 issued and 4 pending patents in the U.S. related to the Allurion Smart Capsule (swallowable, self-deflating, naturally passing gastric balloon, fill/release valves, deployment methods). Additionally, 43 issued and 4 pending patents outside the U.S. (generally paralleling the U.S. portfolio in 17 countries, including 3 Unitary European patents).
• Expiration Dates: Issued patents are expected to expire between February 21, 2033, and November 27, 2040.
• Trademarks: 65 registered trademarks in 40 jurisdictions (medical devices, downloadable software, digital scale, medical services).
• IP Litigation: The medical device industry is characterized by patent litigation, and the Company could become subject to adversarial proceedings.

Technology Partnerships: Not explicitly detailed, but the Company engages consultants and third-party information technology and security providers for its cybersecurity risk management program and AI platform development.

Leadership & Governance

Executive Leadership Team (as of March 17, 2026)

Allurion has treated over 200,000 patients commercially in over 50 countries outside the United States. The global obesity treatment market is projected to reach $54 billion by 2030, with an estimated two billion people globally overweight. The Company estimates a $10 billion total addressable market for the Allurion Smart Capsule in the United States.

Recent strategic developments include the FDA's PMA approval for the Allurion Gastric Balloon System (AGBS) on February 20, 2026, indicating its use for short-term limited weight loss in adults with BMI ≥ 30 kg/m2 and ≤ 40 kg/m2. The Company also completed a warrant exercise inducement offer in February 2026, generating approximately $3.1 million in gross proceeds. In November 2025, Allurion entered into an Exchange Agreement with RTW to convert existing debt and revenue interest obligations into Series B convertible preferred stock, subject to closing conditions. Product innovation in 2024 included a next-generation Allurion Smart Capsule with improved features, and the VCS was launched in the United States in April 2024 for patients using other weight loss treatments. In August 2025, the Company underwent a significant workforce restructuring, reducing its headcount by approximately 65% (70 roles) to optimize operating expenses.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 62.8%
• Operating Margin: -197.9%
• Net Margin: -188.8%

Investment in Growth (2025):

• R&D Expenditure: $7.57 million (49.7% of revenue)
• Capital Expenditures: $0 million
• Strategic Investments: The Company is exploring combination approaches with GLP-1 receptor agonists in future clinical trials.

Business Segment Analysis

Allurion operates its business in a single operating segment and as one reporting unit.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed for 2025 or 2024.
• Dividend Payments: Allurion does not intend to pay cash dividends for the foreseeable future, with any future determination at the discretion of the Board of Directors.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $5.41 million
• Total Debt: $75.77 million (Current portion of convertible notes payable: $28.07 million; Revenue Interest Financing liability: $47.70 million)
• Net Cash Position: $(70.36) million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: RTW Convertible Notes mature on April 16, 2031. The Revenue Interest Financing Agreement matures on December 31, 2030.

Cash Flow Generation (2025):

• Operating Cash Flow: $(28.95) million
• Free Cash Flow: $(28.95) million (Operating Cash Flow - Capital Expenditures)
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Allurion Smart Capsules are manufactured and assembled in-house at the Company's 10,000 square foot, ISO 13485 certified manufacturing facility in Natick, Massachusetts. The operational philosophy emphasizes compliance with FDA's Quality System Regulation ("QSR") and the European Union’s Quality Management Systems requirements (ISO 13485:2016). The Allurion Virtual Care Suite ("VCS") provides digital service delivery, integrating AI-powered remote patient monitoring and a behavior change program.

Supply Chain Architecture: Key Suppliers & Partners:

• Components & Sub-assemblies: Relies on suppliers for extruded film, stylets, filler kits, accessories, and scales. Some critical components are sourced from single suppliers, with whom the Company typically maintains at least a six-month supply.
• Manufacturing: In-house production team in Natick, Massachusetts.
• Sterilization: Relies on third-party providers for sterilization.

Facility Network:

• Corporate Headquarters: Natick, Massachusetts (approx. 9,900 sq ft, lease expires February 28, 2028).
• Manufacturing: Natick, Massachusetts (approx. 10,200 sq ft, lease expires February 28, 2028).
• Research & Development: R&D labs are part of the Natick facilities.
• Distribution: Previously leased warehouse space in Hudson, Massachusetts (9,800 sq ft) which expired on February 28, 2026.

Operational Metrics:

• Quality Indicators: Commercial experience with over 200,000 Allurion Smart Capsule units has shown a serious adverse event ("SAE") rate of less than 0.2%, similar to reported literature.

Market Access & Customer Relationships

Go-to-Market Strategy: Allurion employs a multi-faceted business-to-business-to-consumer ("B2B2C") marketing strategy. Distribution Channels:

• Direct Sales: Operates a direct sales force in approximately 20 countries.
• Channel Partners: Utilizes distributors in certain countries, providing clinical training and support.
• Digital Platforms: The Allurion Virtual Care Suite (VCS) mobile app and clinic dashboard serve as digital platforms for patient support and provider monitoring.

Customer Portfolio: Enterprise Customers: Targets bariatric surgeons, gastroenterologists, plastic surgeons, and other healthcare providers. The Allurion Smart Capsule's procedureless nature allows a wider group of healthcare providers to offer the program.

• Customer Concentration: For 2025, no single customer represented 10% or more of total revenue. For 2024, one customer represented 14% of accounts receivable.

Geographic Revenue Distribution (2025):

• Spain: $2.15 million
• Italy: $1.84 million
• All other countries: $11.24 million (includes five countries each contributing 4%-9% of total revenue, and 44 other countries).
• Growth Markets: Strategy includes deepening global presence in existing markets and launching in new markets, including the United States following FDA approval.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The weight loss and obesity management industries are highly competitive, rapidly changing, and influenced by new product introductions, clinical research, corporate combinations, and regulatory actions. The global obesity treatment market is expected to reach $54 billion by 2030, driven by rising obesity rates (projected one billion obese globally by 2030). GLP-1 receptor agonists have become popular, but face challenges with adherence (30% discontinue in first month, 65% in first year) and muscle mass loss (approx. 40% of total weight lost).

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Intragastric Balloons (outside US): SC MedSil, Medicone, Spatz Laboratories.
• Intragastric Balloons (US): Boston Scientific Corporation (acquired Apollo Endosurgery), ReShape Lifesciences, Inc. (now Medtimo, not currently commercializing), Spatz FGIA Inc. (All require endoscopy and anesthesia for placement and/or removal).
• Pharmaceuticals: Novo Nordisk A/S, Eli Lilly & Co., Roche Holding AG, GlaxoSmithKline plc, Arena Pharmaceuticals, Inc., VIVUS, Inc., Orexigen Therapeutics, Inc.

Emerging Competitive Threats: Compounded GLP-1 drugs and other new or alternative products that are safer, more effective, or easier to use.

Competitive Response Strategy: Allurion aims to overcome limitations of other treatments through its Procedureless™ technology, favorable safety profile, AI-powered end-to-end weight management platform, life-changing clinical outcomes, attractive economics for patients and providers, broad patent portfolio, and proprietary manufacturing capabilities. The Company is also exploring combination approaches with low-dose GLP-1s in future clinical trials to address GLP-1 shortcomings.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Highly competitive and rapidly changing weight loss and obesity management industries. Risk of new product introductions, clinical research, and regulatory changes impacting demand.
• Technology Disruption: Competitors developing safer, more effective, or easier-to-use products (medical devices or drugs like GLP-1s) could reduce or eliminate commercial opportunities.
• Customer Concentration: Dependence on healthcare providers and third-party distributors, with limited direct control over their sales efforts. Failure to collect receivables from them could adversely affect financial position.
• Market Acceptance: Failure of the Allurion Smart Capsule to achieve and maintain market acceptance, especially in the United States where commercial history is limited, could result in sales below expectations.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Dependence on a limited number of single-source suppliers for critical components, sub-assemblies, and materials, making the Company vulnerable to supply shortages and price fluctuations.
• Geographic Concentration: International operations expose the Company to business, regulatory, political, operational, financial, and economic risks in over 50 countries, including emerging markets.
• Capacity Constraints: Need to increase manufacturing capabilities over time to satisfy increased demand, with no experience manufacturing in such quantities.
• Workforce Management: Changes in business and operations, including a significant reduction in force (65% in 2025), place demands on management and infrastructure, potentially leading to delays, decreased satisfaction, or employee attrition.
• Product Liability: Inherent risk of product liability exposure related to the sale or misuse of the Allurion Smart Capsule, potentially leading to costly litigation, reputational harm, or regulatory actions.

Financial & Regulatory Risks

• Going Concern: Recurring operating losses and cash outflows, expectation of continued losses, and noncompliance with financial covenants raise substantial doubt about the Company's ability to continue as a going concern.
• Debt Burden: Significant amount of debt ($75.77 million as of December 31, 2025), with financial covenants (minimum liquidity, minimum revenue) that the Company has been out of compliance with, potentially leading to debt acceleration.
• Funding Availability: Need for additional funds to support operations, which may not be available on acceptable terms or at all, forcing delays or suspension of development and commercialization efforts.
• Regulatory Approval & Compliance: Ongoing regulatory obligations and review post-approval (e.g., FDA PMA approval in US), potential for withdrawal or modification of approvals if adverse events occur, and penalties for non-compliance.
• Reimbursement: Limited third-party reimbursement for products, requiring reliance on self-pay practice management and patients' willingness to pay out-of-pocket.
• Financial Statement Restatement: Previously restated financial statements for multiple periods, leading to unanticipated costs, legal proceedings, regulatory actions, and potential adverse effects on investor confidence and share price.

Geopolitical & External Risks

• Geopolitical Exposure: Unstable global economic and geopolitical conditions (e.g., military conflicts, trade wars) could adversely affect business, financial condition, and results of operations.
• Trade Relations: Changes in U.S. federal policy, including tariffs, could impact global economic conditions and financial markets.
• Climate-related Issues: Evolving government regulations (e.g., SEC Climate Disclosure Rules) may impose additional costs or expose the Company to reputational risks.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Allurion Smart Capsule Enhancements: Focus on improving efficacy and ease of use, including a smaller capsule, more radiopaque catheter, and enhanced fill valve (released in 2024).
• Drug Delivery Platform: Intends to implement new features to potentially enable the Allurion Smart Capsule as a platform technology for drug delivery.
• AI Platform (Allurion Iris): Leverages machine learning for remote patient monitoring, key insights, and workflow streamlining (e.g., Success Predictor, Coach Iris). Innovation Pipeline:
• GLP-1 Combination Trials: Clinical pipeline focused on gathering additional evidence on the safety and efficacy of combining the Allurion Program with low-dose GLP-1 medications, with initial case series showing favorable results (e.g., 20.3% weight loss with semaglutide, 23% with tirzepatide, with muscle mass preservation/increase).

Intellectual Property Portfolio:

• Patent Strategy: Owns or has rights to a broad portfolio of intellectual property.
• Patent Holdings: As of December 31, 2025, 23 issued and 4 pending patents in the U.S. related to the Allurion Smart Capsule (swallowable, self-deflating, naturally passing gastric balloon, fill/release valves, deployment methods). Additionally, 43 issued and 4 pending patents outside the U.S. (generally paralleling the U.S. portfolio in 17 countries, including 3 Unitary European patents).
• Expiration Dates: Issued patents are expected to expire between February 21, 2033, and November 27, 2040.
• Trademarks: 65 registered trademarks in 40 jurisdictions (medical devices, downloadable software, digital scale, medical services).
• IP Litigation: The medical device industry is characterized by patent litigation, and the Company could become subject to adversarial proceedings.

Technology Partnerships: Not explicitly detailed, but the Company engages consultants and third-party information technology and security providers for its cybersecurity risk management program and AI platform development.

Leadership & Governance

Executive Leadership Team (as of March 17, 2026)